{
  "source": "PA-Notification-Stivarga.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1098-14\nProgram Prior Authorization/Notification\nMedication Stivarga® (regorafenib)\nP&T Approval Date 11/2012, 4/2013, 7/2013, 11/2014, 11/2015, 6/2016, 6/2017, 6/2018,\n6/2019, 6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nStivarga (regorafenib) is a kinase inhibitor indicated for the treatment of patients with: metastatic\ncolorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-\nand irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR\ntherapy; locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who\nhave been previously treated with imatinib mesylate (Gleevec) and sunitinib malate (Sutent);\nhepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib\ntosylate).1\nThe National Cancer Comprehensive Network (NCCN) also recommends additional use of\nStivarga in colon cancer, rectal cancer, soft tissue sarcoma, hepatocellular carcinoma, biliary tract\ncancer, bone cancer, gastrointestinal stromal tumor (GIST), and glioblastoma.2\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Stivarga will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Colorectal Cancer (CRC)\n1. Initial Therapy\na. Stivarga will be approved based on all of the following criteria:\n(1) Diagno",
    "t is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Colorectal Cancer (CRC)\n1. Initial Therapy\na. Stivarga will be approved based on all of the following criteria:\n(1) Diagnosis of advanced or metastatic colorectal cancer\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) History of failure, contraindication, or intolerance to treatment with all of the\nfollowing:\n(a) Oxaliplatin-based chemotherapy\n(b) Irinotecan-based chemotherapy\n(c) Anti-VEGF-based chemotherapy\n-AND-\n(3) One of the following:\n(a) Tumor is RAS mutant-type\n-OR-\n(b) Both of the following:\ni. Tumor is RAS wild-type\nii. History of failure, contraindication, or intolerance to anti-EGFR therapy\n[e.g., Erbitux (cetuximab), Vectibix (panitumumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Stivarga will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Stivarga therapy\nAuthorization will be issued for 12 months.\nC. Soft Tissue Sarcoma (STS)\n1. Initial Therapy\na. Stivarga will be approved based on both of the following criteria:\n(1) Diagnosis of soft tissue sarcoma\n-AND-\n(2) One of the following\n(a) Extremity/superficial trunk or head/neck that is non-adipocytic with\nadvanced/metastatic disease with disseminated metastases\n(b) Retroperitoneal/intra-abdominal that is non-adipocytic with recurrent\nunresectable or stage IV disease\n© 2025 UnitedHealthcare Services, Inc.\n2\n(c) Advanced/metastatic pleomorphic rhabdomyosarcoma\n(d) Angiosarcoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Stivarga will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Stivarga therapy\nAuthorization will be issued for 12 months.\nD. Gastrointestinal Stromal Tumor (GIST)\n1. Initial Therapy\na. Stivarga will be approved based on all of the following criteria:\n(1) Diagnosis of gastrointestinal stromal tumor (GIST)\n-AND-\n(2) Disease is one of the",
    "inal Stromal Tumor (GIST)\n1. Initial Therapy\na. Stivarga will be approved based on all of the following criteria:\n(1) Diagnosis of gastrointestinal stromal tumor (GIST)\n-AND-\n(2) Disease is one of the following:\n(a) Gross residual (R2 resection)\n(b) Unresectable primary\n(c) Tumor rupture\n(d) Recurrent/metastatic\n-AND-\n(3) One of the following:\n(a) SDH-deficient GIST\n-OR-\n(b) History of disease progression on both of the following:\ni. Imatinib mesylate (Gleevec)\nii. One of the following\n• Sutent (sunitinib malate)\n• Qinlock (ripretinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n3\na. Stivarga will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Stivarga therapy\nAuthorization will be issued for 12 months.\nE. Hepatobiliary Cancers\n1. Initial Therapy\na. Stivarga will be approved based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of one of the following:\ni. Gallbladder cancer\nii. Extrahepatic cholangiocarcinoma\niii. Intrahepatic cholangiocarcinoma\n-AND-\n(b) Disease is one of the following:\ni. Unresectable\nii. Gross residual (R2)\niii. Metastatic\n-OR-\n(2) Both of the following:\n(a) Diagnosis of hepatocellular carcinoma\n-AND-\n(b) Used as subsequent-line therapy for disease progression\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Stivarga will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Stivarga therapy\nAuthorization will be issued for 12 months.\nF. Bone Cancer\n© 2025 UnitedHealthcare Services, Inc.\n4\n1. Initial Therapy\na. Stivarga will be approved based on both of the following criteria:\n(1) Diagnosis of one of the following bone cancer:\n(a) Dedifferentiated chondrosarcoma\n(b) Ewing Sarcoma\n(c) High grade undifferentiated pleomorphic sarcoma (UPS)\n(d) Mesenchymal chondrosarcoma\n(e) Osteosarcoma\n(f) Other primary round cell tumors of t",
    "(a) Dedifferentiated chondrosarcoma\n(b) Ewing Sarcoma\n(c) High grade undifferentiated pleomorphic sarcoma (UPS)\n(d) Mesenchymal chondrosarcoma\n(e) Osteosarcoma\n(f) Other primary round cell tumors of the bone (e.g., CIC::DUX4,\nBCOR::CCNB3)\n-AND-\n(2) Used as second-line therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Stivarga will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Stivarga therapy\nAuthorization will be issued for 12 months.\nG. Glioblastoma\n1. Initial Therapy\na. Stivarga will be approved based on the following criterion:\n(1) Diagnosis of recurrent or progressive glioblastoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Stivarga will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Stivarga therapy\nAuthorization will be issued for 12 months.\nH. Uterine Sarcoma\n1. Initial Therapy\n© 2025 UnitedHealthcare Services, Inc.\n5\na. Stivarga will be approved based on all of the following criteria:\n(1) Diagnosis of uterine sarcoma\n-AND-\n(2) Disease is one of the following:\n(a) Advanced\n(b) Recurrent/metastatic\n(c) Inoperable\n-AND-\n(3) Used as second-line or subsequent therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Stivarga will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Stivarga therapy\nAuthorization will be issued for 12 months.\nI. NCCN Recommended Regimens\na. The drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprogram",
    "nths.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Stivarga [package insert]. Whippany, NJ: Bayer Healthcare Pharmaceuticals, Inc. February 2025.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed April 28, 2025.\n© 2025 UnitedHealthcare Services, Inc.\n6\nProgram Prior Authorization/Notification – Stivarga (regorafenib)\nChange Control\n9/2014 Administrative change – Tried/Failed exemption for State of New\nJersey removed.\n11/2014 Annual review. Removed VEGF criteria from colorectal cancer and\nadded disease progression. Added progressive to GIST. Updated\nbackground & references.\n11/2015 Annual review. Revised CRC and GIST criteria. Increased\nauthorization from 3 months to 12 month. Updated references.\n6/2016 Annual review. Revised CRC criteria, removing KRAS/NRAS mutant\nrequirement. Updated references.\n6/2017 Annual review. Updated coverage criteria to include hepatocellular\ncancer to align with updated package insert. Updated background,\nformatting and references.\n6/2018 Annual review. Updated references.\n6/2019 Annual review. Updated criteria for colorectal cancer and soft tissue\nsarcoma based on NCCN guidelines. Updated references.\n6/2020 Annual review. Updated criteria for hepatobiliary carcinoma according\nto NCCN guidelines. Addition of osteosarcoma and glioblastoma\naccording to NCCN. Updated references.\n6/2021 Annual review. Updated criteria for soft ti",
    "d criteria for hepatobiliary carcinoma according\nto NCCN guidelines. Addition of osteosarcoma and glioblastoma\naccording to NCCN. Updated references.\n6/2021 Annual review. Updated criteria for soft tissue sarcoma in accordance\nwith NCCN. Updated references.\n6/2022 Annual review. Revised criteria to remove indication for solitary\nfibrous tumor in accordance with NCCN. Updated references.\n6/2023 Annual review. Updated background to include SDH-deficient GIST.\nUpdated STS criteria. Updated hepatobiliary cancers criteria. Updated\nglioblastoma criteria. Updated references. Added state mandate\nfootnote.\n6/2024 Annual review. Added examples to anti-EGFR therapy. Removed\n“criteria” from all reauthorization sections. Separated gastrointestinal\nstromal tumor criteria from soft tissue sarcoma criteria and updated\ncriteria per NCCN guideline. Added disease subtype criteria to\nhepatobiliary cancer section. Changed osteosarcoma section to bone\ncancer and added Ewing Sarcoma to criteria per NCCN guideline.\nUpdated background and reference.\n6/2025 Annual review. Added new indication and coverage criteria for uterine\nsarcoma. Updated coverage criteria for colorectal cancer,\ngastrointestinal stromal tumors, and bone cancer based on NCCN.\nUpdated references.\n© 2025 UnitedHealthcare Services, Inc.\n7"
  ]
}